Delving into disability in Crohn's disease: Dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease

Journal of Crohn's and Colitis

Volumn 8, Issue 7, 2014, Pages 626-634

  Van Langenberg, D R ^a   Gatta, P Della ^b   Hill, B ^b   Zacharewicz, E ^b   Gibson, P R ^a   Russell, A P ^b  

^a MONASH UNIVERSITY   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

Disability; Inflammatory bowel disease; Muscle atrophy; Sarcopenia; Vitamin D

Indexed keywords

AMINOSALICYLIC ACID; C REACTIVE PROTEIN; COLECALCIFEROL; CORTICOSTEROID; FERRITIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; MUSCLE PROTEIN; PROTEIN KINASE B; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; EIF4EBP1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN TYROSINE PHOSPHATASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STS-1 PROTEIN, HUMAN;

ACCELEROMETER; ADULT; ARTICLE; BIOLOGICAL THERAPY; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; EMPLOYMENT STATUS; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTESTINE RESECTION; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE FATIGUE; MUSCLE HYPERTROPHY; MUSCLE MASS; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUADRICEPS FEMORIS MUSCLE; SARCOPENIA; SITTING; SKELETAL MUSCLE; SMOKING; VASTUS LATERALIS MUSCLE; VITAMIN BLOOD LEVEL; WESTERN BLOTTING; BIOPSY; BLOOD; COMPLICATION; HYPERTROPHY; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; MUSCULAR ATROPHY; ORGAN SIZE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; BIOPSY; CHOLECALCIFEROL; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; HUMANS; HYPERTROPHY; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MALE; MIDDLE AGED; MOTOR ACTIVITY; MUSCULAR ATROPHY; ORGAN SIZE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-AKT; QUADRICEPS MUSCLE; SIGNAL TRANSDUCTION;

EID: 84901499277     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.11.024     Document Type: Article

References (38)

1. Stucki G., Bruhlmann P., Stucki S., Michel B.A. Isometric muscle strength is an indicator of self-reported physical functional disability in patients with rheumatoid arthritis. Br J Rheumatol 1998, 37:643-648.
2. Schneider S.M., Al-Jaouni R., Filippi J., Wiroth J.B., Zeanandin G., Arab K., et al. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2008, 14:1562-1568.
3. Wiroth J.B., Filippi J., Schneider S.M., Al-Jaouni R., Horvais N., Gavarry O., et al. Muscle performance in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2005, 11:296-303.
4. Geerling B.J., Badart-Smook A., Stockbrugger R.W., Brummer R.J. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998, 67:919-926.
5. van Langenberg D.R., Della Gatta P., Hill B., Zacharewicz E., Gibson P.R., Russell A.P. Objectively measured muscle fatigue in Crohn's disease: correlation with self-reported fatigue and associated factors for clinical application. J Crohns Colitis 2014, 8:137-146.
6. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001, 3:1009-1013.
7. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403.
8. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
9. Latres E., Amini A.R., Amini A.A., Griffiths J., Martin F.J., Wei Y., et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005, 280:2737-2744.
10. Reimund J.M., Wittersheim C., Dumont S., Muller C.D., Baumann R., Poindron P., et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996, 16:144-150.
11. Cominelli F. Cytokine-based therapies for Crohn's disease-new paradigms. New Engl J Med 2004, 351:2045-2048.
12. Visser M., Pahor M., Taaffe D.R., Goodpaster B.H., Simonsick E.M., Newman A.B., et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol Biol Sci Med Sci 2002, 57:M326-M332.
13. Schaap L.A., Pluijm S.M., Deeg D.J., Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006, 119:526 e9-17.
14. Leger B., Vergani L., Soraru G., Hespel P., Derave W., Gobelet C., et al. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. FASEB J 2006, 20:583-585.
15. Doucet M., Russell A.P., Leger B., Debigare R., Joanisse D.R., Caron M.A., et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:261-269.
16. Leger B., Derave W., De Bock K., Hespel P., Russell A.P. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 2008, 11:163-175B.
17. Iwase H. Determination of vitamin K1 in emulsified nutritional supplements by solid-phase extraction and high-performance liquid chromatography with postcolumn reduction on a platinum catalyst and fluorescence detection. J Chromatogr 2000, 881:261-266.
18. Iwase H. Determination of vitamin D2 in emulsified nutritional supplements by solid-phase extraction and column-switching high-performance liquid chromatography with UV detection. J Chromatogr 2000, 881:189-196.
19. Ciarcia G., Paolucci M., Guerriero G., Cozzolino G., Abrescia P. Determination of vitamin E in eggs and during the larval development of the sea bass, Dicentrarchus labrax by high performance liquid chromatography. Biofactors 2000, 11:19-21.
20. Visser M., Deeg D.J., Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003, 88:5766-5772.
21. Dominguez L.J., Barbagallo M., Lauretani F., Bandinelli S., Bos A., Corsi A.M., et al. Magnesium and muscle performance in older persons: the InCHIANTI study. Am J Clin Nutr 2006, 84:419-426.
22. Russell A.P., Wadley G., Hesselink M.K., Schaart G., Lo S., Leger B., et al. UCP3 protein expression is lower in type I, IIa and IIx muscle fiber types of endurance-trained compared to untrained subjects. Eur J Physiol 2003, 445:563-569.
23. Leger B., Cartoni R., Praz M., Lamon S., Deriaz O., Crettenand A., et al. Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2006, 576:923-933.
24. Cannata D.J., Ireland Z., Dickinson H., Snow R.J., Russell A.P., West J.M., et al. Maternal creatine supplementation from mid-pregnancy protects the newborn spiny mouse diaphragm from intrapartum hypoxia-induced damage. Pediatr Res 2010, 68:393-398.
25. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
26. Alempijevic T., Jovanovic I., Popovic D., Kovacevic N., Milutinovic A.S., Krstic M. IGF-I as a marker of disease activity and nutritional status in patients with inflammatory bowel disease. Indian J Gastroenterol 2008, 27:247-248.
27. Street M.E., de'Angelis G., Camacho-Hubner C., Giovannelli G., Ziveri M.A., Bacchini P.L., et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 2004, 61:159-164.
28. Bodell P.W., Kodesh E., Haddad F., Zaldivar F.P., Cooper D.M., Adams G.R. Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. J Appl Physiol 2009, 106:443-453.
29. Haddad F., Zaldivar F., Cooper D.M., Adams G.R. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005, 98:911-917.
30. Lazarus D.D., Moldawer L.L., Lowry S.F. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res 1993, 12:219-223.
31. Zhang L., Du J., Hu Z., Han G., Delafontaine P., Garcia G., et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009, 20:604-612.
32. Semba R.D., Ferrucci L., Sun K., Walston J., Varadhan R., Guralnik J.M., et al. Oxidative stress and severe walking disability among older women. Am J Med 2007, 120:1084-1089.
33. Howard C., Ferrucci L., Sun K., Fried L.P., Walston J., Varadhan R., et al. Oxidative protein damage is associated with poor grip strength among older women living in the community. J Appl Physiol 2007, 103:17-20.
34. 2 release increases with age in human vastus lateralis muscle although oxidative capacity is preserved. Mech Ageing Dev 2005, 126:505-511.
35. Beltran B., Nos P., Dasi F., Iborra M., Bastida G., Martinez M., et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease. Inflamm Bowel Dis 2010, 16:76-86.
36. Boirivant M., Marini M., Di Felice G., Pronio A.M., Montesani C., Tersigni R., et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999, 116:557-565.
37. Russell S.T., Eley H.L., Wyke S.M., Tisdale M.J. Involvement of phosphoinositide 3-kinase and Akt in the induction of muscle protein degradation by proteolysis-inducing factor. Biochem J 2008, 409:751-759.
38. Foletta V.C., Prior M.J., Stupka N., Carey K., Segal D.H., Jones S., et al. NDRG2, a novel regulator of myoblast proliferation, is regulated by anabolic and catabolic factors. J Physiol 2009, 587:1619-1634.